Avadel Pharmaceuticals PLC
AVDL11.060USD
-0.020-0.18%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.07BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Avadel Pharmaceuticals PLC Unternehmen
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Unternehmensinformationen
BörsenkürzelAVDL
Name des UnternehmensAvadel Pharmaceuticals PLC
IPO-datumJan 16, 1952
CEOMr. Gregory J. (Greg) Divis, Jr.
Anzahl der mitarbeiter188
WertpapierartOrdinary Share
GeschäftsjahresendeJan 16
AddresseBlock 10-1 Blanchardstown Corporate Park
StadtDUBLIN
BörseNASDAQ Global Market Consolidated
LandIreland
Postleitzahl15
Telefon35319015201
Websitehttps://www.avadel.com/
BörsenkürzelAVDL
IPO-datumJan 16, 1952
CEOMr. Gregory J. (Greg) Divis, Jr.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Eric J. Ende, M.D.
Dr. Eric J. Ende, M.D.
Independent Director
Independent Director
219.90K
+5.27%
Mr. Peter J. Thornton
Mr. Peter J. Thornton
Independent Director
Independent Director
115.06K
+10.57%
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Independent Director
Independent Director
89.03K
+14.10%
Mr. Thomas S. Mchugh
Mr. Thomas S. Mchugh
Chief Financial Officer
Chief Financial Officer
87.80K
-12.55%
Ms. Linda S. Palczuk
Ms. Linda S. Palczuk
Independent Director
Independent Director
78.90K
+16.20%
Ms. Susan Rodriguez
Ms. Susan Rodriguez
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Jerad Seurer
Mr. Jerad Seurer
General Counsel and Corporate Secretary
General Counsel and Corporate Secretary
--
--
Mr. Gregory J. (Greg) Divis, Jr.
Mr. Gregory J. (Greg) Divis, Jr.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Naseem Amin, M.D.
Dr. Naseem Amin, M.D.
Independent Director
Independent Director
--
--
Ms. Courtney Turiano
Ms. Courtney Turiano
Investor Relations
Investor Relations
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Eric J. Ende, M.D.
Dr. Eric J. Ende, M.D.
Independent Director
Independent Director
219.90K
+5.27%
Mr. Peter J. Thornton
Mr. Peter J. Thornton
Independent Director
Independent Director
115.06K
+10.57%
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Independent Director
Independent Director
89.03K
+14.10%
Mr. Thomas S. Mchugh
Mr. Thomas S. Mchugh
Chief Financial Officer
Chief Financial Officer
87.80K
-12.55%
Ms. Linda S. Palczuk
Ms. Linda S. Palczuk
Independent Director
Independent Director
78.90K
+16.20%
Ms. Susan Rodriguez
Ms. Susan Rodriguez
Chief Operating Officer
Chief Operating Officer
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Mar 3
Währung: USDAktualisiert: Mon, Mar 3
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Vazculep
10.43M
46.70%
Akovaz
9.54M
42.74%
Bloxiverz
2.20M
9.85%
Other
159.00K
0.71%
Nach RegionUSD
Name
Umsatz
Anteil
United States
22.33M
100.00%
Ireland
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Vazculep
10.43M
46.70%
Akovaz
9.54M
42.74%
Bloxiverz
2.20M
9.85%
Other
159.00K
0.71%
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Janus Henderson Investors
14.03%
Tontine Asset Management, LLC
6.32%
Brandes Investment Partners, L.P.
5.85%
The Vanguard Group, Inc.
5.74%
Two Seas Capital LP
5.10%
Other
62.95%
Aktionäre
Aktionäre
Anteil
Janus Henderson Investors
14.03%
Tontine Asset Management, LLC
6.32%
Brandes Investment Partners, L.P.
5.85%
The Vanguard Group, Inc.
5.74%
Two Seas Capital LP
5.10%
Other
62.95%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
28.13%
Investment Advisor
26.80%
Hedge Fund
20.94%
Individual Investor
4.83%
Venture Capital
3.82%
Research Firm
2.59%
Pension Fund
0.47%
Bank and Trust
0.38%
Insurance Company
0.03%
Other
12.03%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
372
85.19M
87.92%
-22.67M
2025Q1
377
85.31M
88.05%
-24.78M
2024Q4
354
86.56M
89.59%
-16.46M
2024Q3
334
81.87M
84.98%
-15.41M
2024Q2
299
81.11M
84.30%
-2.77M
2024Q1
258
76.98M
80.25%
+5.42M
2023Q4
226
62.92M
70.15%
-3.93M
2023Q3
220
60.11M
69.62%
-5.86M
2023Q2
213
57.67M
66.98%
-1.24M
2023Q1
201
54.14M
84.38%
+9.93M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Janus Henderson Investors
13.59M
14.03%
-487.88K
-3.47%
Mar 31, 2025
Tontine Asset Management, LLC
6.13M
6.32%
-203.28K
-3.21%
Mar 31, 2025
Brandes Investment Partners, L.P.
5.67M
5.85%
+3.49M
+160.78%
Mar 31, 2025
The Vanguard Group, Inc.
3.88M
4.01%
-52.69K
-1.34%
Mar 31, 2025
Two Seas Capital LP
4.95M
5.1%
+650.00K
+15.13%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.69M
4.84%
-55.04K
-1.16%
Mar 31, 2025
Polar Capital LLP
4.36M
4.5%
-58.24K
-1.32%
Mar 31, 2025
Kotler (Kevin)
3.72M
3.84%
-1.01M
-21.37%
Feb 12, 2024
Vivo Capital, LLC
2.68M
2.77%
--
--
Mar 31, 2025
Wealth Effects LLC
2.37M
2.44%
+24.99K
+1.07%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Invesco Pharmaceuticals ETF
2.64%
iShares Neuroscience and Healthcare ETF
1.92%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.11%
Invesco Nasdaq Biotechnology ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.1%
Nuveen ESG Small-Cap ETF
0.07%
Fidelity Enhanced Small Cap ETF
0.07%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.06%
Federated Hermes MDT Small Cap Core ETF
0.05%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.05%
Mehr Anzeigen
Invesco Pharmaceuticals ETF
Anteil2.64%
iShares Neuroscience and Healthcare ETF
Anteil1.92%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.11%
Invesco Nasdaq Biotechnology ETF
Anteil0.1%
ProShares Ultra Nasdaq Biotechnology
Anteil0.1%
Nuveen ESG Small-Cap ETF
Anteil0.07%
Fidelity Enhanced Small Cap ETF
Anteil0.07%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Anteil0.06%
Federated Hermes MDT Small Cap Core ETF
Anteil0.05%
JPMorgan BetaBuilders US Small Cap Equity ETF
Anteil0.05%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
